caution preview tavr result miss street estim
doubt underli market remain strong result
light quarter make us question market
growth tad less expect share slightli shift even
manag maintain upbeat tone chang
tavr guidanc buy pt lotu
approv tonight think combin weak
although earli feedback pascal foster
manag confid outlook feel hit
revenu year lofti goal posit side would point
manag bullish revenu ramp solid
expens control drive ep beat thing consid maintain
neutral recommend
near-term catalyst appear limit management would say
whether seen stark chang physician interest heel
fair week expect fda
approv low-risk later year maintain turn
potenti catalyst outcom pascal present
dgk data unveil later europcr
may timelin pascal trial steadi
updat trial design fmr curiou
would look like post mitraclip result
tweak revenu casm trim tavr
estim miss increas overal sale casm
although expect opex spend ramp cours
year encourag strong start lift overal
valuat maintain neutral risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
adj ww thv revenu came conserv
forecast street estim compani longer
break vs ou tavr perform dollar manag estim
 tavr procedur grew low double-digit ew in-lin
market ou tavr procedur improv low double-digit
ew perform market growth ew manag
candid cede y/i share due price competit
note ew share stabl sequenti edward attribut
momentum newer smaller center turn sapien ultra manag
point posit commerci feedback acknowledg
differ sheath somewhat challeng physician learn
manag continu focu control commerci launch
respect centera europ compani admit also pace
launch vs prior plan ad train proctor plan
ramp commerci launch later year
adj gross margin model better gross margin
perform driven fx benefit product mix exclud
special adjust sg margin well
forecast meanwhil adj margin lower
forecast despit higher spend pascal relat y/i compani
expect expens ramp cours year adj ebit
margin higher model lower tax rate
vs forecast help ep sum adj ep
higher model
actualsbtig estimate variancethv valv revenu heart valv revenu million adj consign revenu revenu expens expens net dilut gross margin bpssg margin bpsr spend bpsadj ebit margin bpstax rate bpssourc btig research estim compani filingsal metric present herein non-gaap basi margin estim non-gaap basi varianc
revenu rais revenu estim contribut
casm critic trim tavr forecast given
respect ep maintain gross margin trim opex
adj ep forecast move
princip beat
edward rate neutral feel ew current market capit
price lead market share fulli penetr matur tavr
market year signific mitral sale btig provid
price target neutral-r stock risk includ competit patent
litig slippag product timelin chang procedur
reimburs futur devic data fda possibl multipl
exhibit comp tabl larg cap med-tech compani
newnewold growth incom ep growth btig research estim compani filingsntm johnsonjnjnot bdxnot scientificbsxbuy lifesciencesewneutr factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
edward incom revenu inc thv return y/i good gross sg other- total oper oper incom ex interest interest expens pre-tax incom tax non-gaap net non-gaap share ex marginsgross net total total total oper tax ep btig estim compani report
edward gaap revenu us y/i ou y/i heart valv y/i heart valv y/i y/i gaap net y/i non-gaap revenu us y/i ou y/i heart valv y/i heart valv y/i y/i non-gaap net y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
